Beta Drugs delivered exceptional profitability performance in the June 2026 quarter, with consolidated net profit rising 35.04% to ₹15.80 crore compared to ₹11.70 crore in the same quarter of the previous year. According to the latest financial data from Business Standard, this profit surge demonstrates the company's ability to maintain strong operational performance despite market challenges.
The company experienced a significant revenue recovery with sales rising 25.29% to ₹125.55 crore in Q1 FY2026, up from ₹100.21 crore in the corresponding quarter of the previous financial year. As reported by Business Standard, this revenue growth indicates successful business expansion and improved market positioning during the quarter.
Operating profit margin (OPM) improved to 21.80% in the June 2026 quarter compared to 19.66% in the same quarter of the previous year. According to the latest financial data from Business Standard, this margin expansion demonstrates enhanced operational efficiency and improved cost management capabilities across the company's operations.
Profit before depreciation and tax (PBDT) increased by 36% to ₹26.39 crore from ₹19.37 crore in the corresponding quarter of the previous year. As reported by Business Standard, profit before tax (PBT) grew 41% to ₹22.04 crore compared to ₹15.65 crore in Q1 FY2025, indicating strong operational performance across all profitability metrics and reflecting the company's improved financial health.
